Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 273 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 273 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $140.55, for a total value of $38,370.15. Following the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at approximately $1,055,108.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ingrid Delaet also recently made the following trade(s):

• On Thursday, March 21st, Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00.
• On Monday, March 11th, Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $140.00, for a total transaction of $28,000.00.
• On Friday, March 8th, Ingrid Delaet sold 1,800 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $140.03, for a total transaction of $252,054.00.
• On Thursday, February 29th, Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $135.51, for a total transaction of $36,994.23.

Neurocrine Biosciences Trading Up 0.3 %

NBIX stock opened at $139.50 on Thursday. The firm has a market cap of $14.04 billion, a PE ratio of 38.30 and a beta of 0.28. Neurocrine Biosciences, Inc. has a 1 year low of $89.04 and a 1 year high of $148.37. The company has a fifty day simple moving average of $137.72 and a 200 day simple moving average of $129.51.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.88 earnings per share. As a group, analysts forecast that Neurocrine Biosciences, Inc. will post 4.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on NBIX. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Wedbush reiterated an “outperform” rating and issued a $147.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 17th. Oppenheimer boosted their price objective on Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. Canaccord Genuity Group raised their target price on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Finally, Mizuho boosted their price target on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a report on Thursday, February 8th. Six analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $147.88.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP acquired a new position in Neurocrine Biosciences during the fourth quarter valued at approximately $105,408,000. Los Angeles Capital Management LLC raised its holdings in Neurocrine Biosciences by 66.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock worth $121,007,000 after acquiring an additional 364,986 shares during the period. Assenagon Asset Management S.A. lifted its position in Neurocrine Biosciences by 120.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 584,539 shares of the company’s stock worth $65,761,000 after acquiring an additional 319,564 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in Neurocrine Biosciences by 73.0% during the 3rd quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock worth $73,045,000 after acquiring an additional 273,952 shares during the last quarter. Finally, Norges Bank bought a new stake in Neurocrine Biosciences during the fourth quarter valued at about $35,731,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.